Morgan Stanley
MS
$220.83
+1.31%
Morgan Stanley is a global financial services firm operating in the Financial - Capital Markets industry, with core businesses spanning investment banking, institutional trading, wealth management, and asset management. The company is a market leader, distinguished by its transformation into a bank holding company with a top-tier wealth and asset management franchise that now generates the lion's share of its income. The current investor narrative centers on the firm's performance amidst a reopening capital markets environment, with recent news highlighting the 'SpaceX IPO machine' as a potential catalyst for its investment banking division, while broader market attention is on bank stress tests and the potential for shareholder capital returns.…
MS
Morgan Stanley
$220.83
Related headlines
Investment Opinion: Should I buy MS Today?
Rating & Thesis: Hold. Morgan Stanley is a high-quality financial institution with a leading wealth management franchise, but its stock price has run up significantly, pricing in much of the near-term optimism around capital markets reopening, leaving a balanced risk/reward profile at current levels. Analyst consensus appears constructively bullish with 'Overweight' and 'Outperform' ratings, though a specific average target price is not provided to quantify implied upside.
Supporting Evidence: The valuation is reasonable but not compelling, with a trailing PE of 16.54x sitting in the mid-range of its own history. Profitability is strong (15.10% ROE) and revenue grew 11.08% YoY in Q4, though this showed sequential deceleration. The PEG ratio of 0.58 is attractive and suggests growth may be undervalued. However, these positives are counterbalanced by high financial leverage (D/E of 4.26) and the stock's position just 2.3% below its 52-week high, limiting the margin of safety.
Risks & Conditions: The two biggest risks are a sharp pullback from overbought technical levels and an earnings slowdown if capital markets activity wanes. This Hold rating would upgrade to a Buy if the PE multiple compressed toward the lower end of its historical range (e.g., below 14x) on a market pullback, or if revenue growth re-accelerates above 15% consistently. It would downgrade to Sell if the technical uptrend breaks decisively below key support (e.g., the $180 level) on deteriorating fundamentals. Relative to its own history and growth profile, the stock is fairly valued at present.
Sign up to view all
MS 12-Month Price Forecast
The AI assessment is neutral based on a balanced set of factors. The powerful technical rally and premium pricing offset the underlying strength of the business model and attractive PEG ratio. The stance is grounded in the expectation of consolidation as the market digests the recent gains and awaits confirmation that earnings can grow into the valuation. The outlook would turn bullish on a successful breakout above the $219 resistance with volume, coupled with accelerating investment banking revenue. It would turn bearish on a breakdown below key technical support around $180, which would likely coincide with deteriorating capital markets fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $287.08 and implied upside of +30.0% versus the current price.
Average Target
$287.08
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$177 - $287
Analyst target range
Analyst coverage for Morgan Stanley appears limited in the provided dataset, with only 7 analysts contributing to estimates for revenue and EPS. The consensus leans bullish, as evidenced by recent institutional ratings from firms like Barclays and Keefe, Bruyette & Woods maintaining 'Overweight' and 'Outperform' ratings, respectively, though JP Morgan has a 'Neutral' stance. Without a provided average target price, the implied upside or downside cannot be calculated, but the estimated revenue range for the period is between $90.46 billion and $96.38 billion, with an average of $93.90 billion, indicating a moderate spread of about 6.3% around the consensus, which signals reasonable analyst agreement. The pattern of recent ratings shows stability, with no major downgrades in the provided data, suggesting institutional analysts are maintaining a constructive view on the stock's prospects.
Bulls vs Bears: MS Investment Factors
The evidence currently leans bullish, driven by strong technical momentum, a profitable and resilient wealth management business, and a favorable PEG ratio suggesting growth is undervalued. However, the bear case presents significant counterpoints, primarily around the stock's extended valuation near all-time highs and the inherent volatility and leverage of the financial business model. The single most important tension in the investment debate is whether the premium valuation, supported by the recent powerful rally and reopening capital markets narrative, can be sustained in the face of potential economic headwinds or a normalization of capital markets activity. The resolution of this tension—specifically, whether earnings growth can accelerate to justify the price—will determine the stock's direction.
Bullish
- Strong Wealth Management Franchise: Wealth Management generated $8.43B in Q4 2025, underpinning the firm's stable, fee-based income stream. This segment, alongside $9.3T in client assets, provides a resilient earnings base less volatile than capital markets.
- Robust Profitability & ROE: The company maintains high profitability with a Q4 net margin of 15.44% and a Return on Equity of 15.10%. This indicates efficient use of shareholder capital and the ability to generate strong returns from its business model.
- Powerful Technical Momentum: The stock is up 62.25% over the past year and 38.21% over three months, significantly outperforming the SPY. Trading at 97.7% of its 52-week high signals strong investor conviction and a sustained uptrend.
- Attractive PEG Ratio: With a PEG ratio of 0.58, the stock appears undervalued relative to its earnings growth expectations. This suggests the market may not be fully pricing in the firm's growth trajectory.
Bearish
- Valuation Near All-Time Highs: The stock trades at $214.04, just 2.3% below its 52-week high of $219.16. This positioning raises risks of a technical pullback and leaves limited near-term upside without a significant catalyst.
- High Financial Leverage: A debt-to-equity ratio of 4.26 is typical for banks but exposes the firm to interest rate risk and credit tightening. This leverage amplifies downside risk during financial stress or economic downturns.
- Revenue & Margin Volatility: Q4 revenue of $28.86B declined sequentially from Q3's $30.05B, and net margin has fluctuated from 12.57% to 15.44% over recent quarters. This highlights sensitivity to capital markets activity and economic cycles.
- Negative Free Cash Flow: Trailing-twelve-month free cash flow is negative $17.89B, reflecting significant investing activities typical for a bank. While not unusual, it limits financial flexibility compared to firms generating consistent positive FCF.
MS Technical Analysis
The stock is in a sustained uptrend, evidenced by a 62.25% gain over the past year, and is currently trading near the top of its 52-week range, approximately 97.7% of the way from its low of $128.81 to its high of $219.16. This positioning near all-time highs signals strong momentum but also raises concerns about potential overextension and vulnerability to a pullback. Recent momentum is exceptionally strong, with the stock up 10.43% over the past month and 38.21% over the past three months, significantly outpacing the SPY's returns of -0.08% and 12.0%, respectively, indicating powerful relative strength and a clear acceleration from the longer-term trend. Key technical support is anchored at the 52-week low of $128.81, while immediate resistance is at the 52-week high of $219.16; a decisive breakout above this level would signal a continuation of the bullish trend, whereas a failure could lead to consolidation. With a beta of 1.221, the stock is approximately 22% more volatile than the broader market, which investors must factor into position sizing and risk management.
Beta
1.22
1.22x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$130-$222
Price range past year
Annual Return
+68.7%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | +14.7% | +1.5% |
| 3m | +38.9% | +13.4% |
| 6m | +27.7% | +10.9% |
| 1y | +68.7% | +24.5% |
| ytd | +21.4% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Revenue growth is positive but has shown some sequential deceleration; the most recent Q4 2025 revenue was $28.86 billion, representing a solid 11.08% year-over-year increase, though this follows a Q3 revenue of $30.05 billion, indicating a quarter-on-quarter decline. The Wealth Management segment, at $8.43 billion for the period, and Institutional Securities, at $7.93 billion, are the primary revenue drivers, with Investment Management contributing a smaller $1.72 billion. The company is highly profitable, with Q4 net income of $4.40 billion and a robust gross margin of 58.02%; however, net margin has fluctuated across recent quarters from 12.57% in Q2 to 15.44% in Q4, reflecting some volatility in profitability linked to capital markets activity. Balance sheet health is a mixed picture: the firm carries a high debt-to-equity ratio of 4.26, typical for a leveraged financial institution, but maintains a solid current ratio of 1.17 for liquidity. Free cash flow on a TTM basis is negative at -$17.89 billion, which is not unusual for a bank due to significant investing activities, but the Return on Equity of 15.10% indicates efficient use of shareholder capital.
Quarterly Revenue
$28.9B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$-17.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 16.54x, while the forward PE is slightly higher at 16.84x; this minimal gap suggests the market is pricing in stable, but not accelerating, earnings growth expectations for the near term. Compared to sector averages, Morgan Stanley's trailing PE of 16.54x and Price-to-Sales (PS) ratio of 2.43x are not directly comparable without a provided industry benchmark, but the stock's valuation must be assessed relative to its own historical context and growth profile. Historically, the stock's own trailing PE has ranged from lows near 8.5x in early 2021 to highs above 24x in late 2023; the current PE of 16.54x sits comfortably in the mid-range of its own history, suggesting the market is neither excessively optimistic nor pessimistic about its earnings power at this juncture.
PE
16.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Morgan Stanley's primary financial risk stems from its high leverage, with a debt-to-equity ratio of 4.26, which magnifies losses during downturns and increases sensitivity to rising interest rates. Profitability is also volatile, as evidenced by net margin swinging from 12.57% to 15.44% across recent quarters, tied directly to the cyclicality of investment banking and trading revenues. While the wealth management segment provides stability, the firm remains exposed to earnings shocks from a slowdown in capital markets activity, which could pressure its valuation multiples.
Market & Competitive Risks: The stock trades at a trailing PE of 16.54x, which is in the mid-range of its own historical spectrum (8.5x to 24x), but the price is near its 52-week high, creating valuation compression risk if growth expectations disappoint. Its beta of 1.221 indicates it is more volatile than the market and susceptible to sector-wide sell-offs in financials. Competitive and regulatory risks are ever-present, with upcoming bank stress tests in late June serving as a near-term catalyst that could impact capital return plans, though recent news suggests a favorable environment for shareholder rewards.
Worst-Case Scenario: A severe recession coupled with a prolonged capital markets freeze could trigger a chain of events: investment banking fees collapse, trading revenues plummet, and wealth management assets under management shrink. This would lead to significant earnings misses, analyst downgrades, and multiple compression. The realistic downside could see the stock re-test its 52-week low of $128.81, representing a potential loss of approximately -40% from the current price of $214.04. The historical max drawdown of -19.28% provides a reference for a less severe but still painful correction.
FAQ
The key risks are, in order of severity: 1) Financial & Cyclical Risk: High debt-to-equity (4.26) and earnings volatility tied to capital markets; a recession could sharply cut profits. 2) Valuation & Technical Risk: Trading near 52-week highs after a major rally increases vulnerability to a sharp correction, as seen in its 19.28% max drawdown. 3) Competitive & Regulatory Risk: Intense competition in wealth and investment banking, plus regulatory scrutiny from upcoming stress tests that could limit capital returns. 4) Market Risk: A beta of 1.221 means it typically falls more than the market during broad sell-offs.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $190 and $219 as earnings grow steadily. The Bull Case (30% probability) targets $219 to $240, driven by a booming IPO market and strong capital returns. The Bear Case (15% probability) warns of a drop to $129-$175 if the economy slows and capital markets freeze. The Base Case is most likely, assuming the current favorable environment for financials persists without significant deterioration. The key assumption is that wealth management stability offsets any volatility in investment banking.
MS appears fairly valued relative to its own history. The trailing PE of 16.54x sits comfortably in the mid-range of its historical spectrum, which has ranged from approximately 8.5x to over 24x. The PEG ratio of 0.58 suggests its earnings growth may be undervalued. However, the Price-to-Sales ratio of 2.43x and the stock's proximity to its 52-week high suggest the market is not offering a discount. The valuation implies the market expects steady, mid-single-digit earnings growth and a continuation of the current favorable capital markets environment, but not a significant acceleration.
MS is a Hold, not a clear-cut buy at current levels. The stock has had a tremendous run, up 62.25% over the past year and trading just 2.3% below its all-time high, which limits the near-term margin of safety. While the underlying business is strong with a 15.10% ROE and an attractive PEG ratio of 0.58, the high financial leverage (D/E of 4.26) and cyclical earnings profile add risk. It could be a good buy for investors with a long-term horizon on a meaningful pullback, but entering at the peak of a rally carries heightened risk of short-term underperformance.
MS is more suitable for a long-term investment horizon of 3-5 years rather than short-term trading. Its business model benefits from long-term asset gathering in wealth management and client relationships in banking, which compound over time. However, its high beta (1.221) and cyclicality introduce significant short-term volatility, making it a challenging trade. The modest dividend yield of 2.36% provides some income but is not the primary attraction. Given the current valuation near highs, a long-term holder can weather potential consolidation phases, while a short-term trader faces heightened risk from momentum shifts.
